IL323171A - הרכבים ושיטות לאפנון אפיגנטי של ביטוי pcsk9 - Google Patents

הרכבים ושיטות לאפנון אפיגנטי של ביטוי pcsk9

Info

Publication number
IL323171A
IL323171A IL323171A IL32317125A IL323171A IL 323171 A IL323171 A IL 323171A IL 323171 A IL323171 A IL 323171A IL 32317125 A IL32317125 A IL 32317125A IL 323171 A IL323171 A IL 323171A
Authority
IL
Israel
Prior art keywords
domain
sequence
seq
human
dna
Prior art date
Application number
IL323171A
Other languages
English (en)
Original Assignee
Nchroma Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nchroma Bio Inc filed Critical Nchroma Bio Inc
Publication of IL323171A publication Critical patent/IL323171A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL323171A 2023-03-06 2025-09-04 הרכבים ושיטות לאפנון אפיגנטי של ביטוי pcsk9 IL323171A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363488736P 2023-03-06 2023-03-06
PCT/US2024/018670 WO2024186896A2 (en) 2023-03-06 2024-03-06 Compositions and methods for epigenetic regulation of pcsk9 expression

Publications (1)

Publication Number Publication Date
IL323171A true IL323171A (he) 2025-11-01

Family

ID=92675704

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323171A IL323171A (he) 2023-03-06 2025-09-04 הרכבים ושיטות לאפנון אפיגנטי של ביטוי pcsk9

Country Status (8)

Country Link
EP (1) EP4677082A2 (he)
JP (1) JP2026510339A (he)
KR (1) KR20260022497A (he)
CN (1) CN121889501A (he)
AU (1) AU2024230979A1 (he)
IL (1) IL323171A (he)
MX (1) MX2025010510A (he)
WO (1) WO2024186896A2 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL324634A (he) 2023-05-15 2026-01-01 Nchroma Bio Inc תכשירים ושיטות לוויסות אפיגנטי של ביטוי גן hbv

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158985A2 (en) * 2011-05-17 2012-11-22 Transposagen Biopharmaceuticals, Inc. Methods for site-specific genetic modification in spermatogonial stem cells using zinc finger nuclease (zfn) for the creation of model organisms
US20160040163A1 (en) * 2013-03-15 2016-02-11 Pronai Therapeutics, Inc. Dnai for the modulation of genes
CA2947904A1 (en) * 2015-11-12 2017-05-12 Pfizer Inc. Tissue-specific genome engineering using crispr-cas9
US10465187B2 (en) * 2017-02-06 2019-11-05 Trustees Of Boston University Integrated system for programmable DNA methylation
CA3202977A1 (en) * 2020-12-22 2022-06-30 Chroma Medicine, Inc. Compositions and methods for epigenetic editing
EP4288548A4 (en) * 2021-02-05 2025-01-15 Dharmacon, Inc. FUSION PROTEINS FOR CRISPR-BASED TRANSCRIPTION REPRESSION
WO2023017004A1 (en) * 2021-08-09 2023-02-16 Cargene Therapeutics Pte. Ltd. Inhibitory nucleic acids for pcsk9

Also Published As

Publication number Publication date
WO2024186896A2 (en) 2024-09-12
EP4677082A2 (en) 2026-01-14
KR20260022497A (ko) 2026-02-19
CN121889501A (zh) 2026-04-17
AU2024230979A1 (en) 2025-10-16
MX2025010510A (es) 2026-02-03
JP2026510339A (ja) 2026-04-02
WO2024186896A3 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
CA3251776A1 (en) COMPOSITIONS AND METHODS FOR THE EPIGENETIC REGULATION OF PCSK9 EXPRESSION
US20240132855A1 (en) Compositions and methods for epigenetic regulation of hbv gene expression
IL323171A (he) הרכבים ושיטות לאפנון אפיגנטי של ביטוי pcsk9
US20250387518A1 (en) Compositions and methods for epigenetic regulation of b2m expression
US12390538B2 (en) Compositions and methods for epigenetic regulation of HBV gene expression
WO2024229020A2 (en) Compositions and methods for epigenetic regulation of pcsk9 expression
US20250236847A1 (en) Compositions and methods for epigenetic regulation of hbv gene expression
WO2024145615A2 (en) Compositions and methods for epigenetic regulation of angptl3 expression
US20250387514A1 (en) Compositions and methods for epigenetic regulation of trac expression
WO2025030130A1 (en) Methods and compositions comprising dnmt3a-binding antibodies
WO2024081879A1 (en) Compositions and methods for epigenetic regulation of cd247 expression
WO2025049303A1 (en) Compositions and methods for epigenetic regulation
WO2025049789A1 (en) Compositions and methods for epigenetic regulation of adora2a expression
WO2025101979A1 (en) Compositions and methods for epigenetic regulation of genes for treatment of non-alcoholic steatohepatitis or metabolic dysfunction-associated steatohepatitis
JP2025525389A (ja) Ｃｉｉｔａ発現のエピジェネティック調節のための組成物及び方法
WO2024238679A9 (en) Compositions and methods for epigenetic regulation of cd3gamma, cd3delta, and rfx5 expression
WO2025049792A1 (en) Compositions and methods for epigenetic regulation of tgfbr2 expression
HK40128700A (zh) 用於表观遗传调控hbv基因表达的组合物和方法
WO2025019807A2 (en) Compositions and methods for epigenetic regulation of rfxap expression